利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.018 秒)

    Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
    3.
    发明授权
    Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy 有权
    人源化α-烯醇酶特异性抗体及其在癌症治疗中的应用方法

    公开(公告)号：US09527922B2

    公开(公告)日：2016-12-27

    申请号：US14588212

    申请日：2014-12-31

    申请人： Development Center for Biotechnology ,  DCB-USA LLC ,  National Health Research Institutes

    发明人： Shih-Chong Tsai ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Jiann-Shiun Lai ,  Chia-Cheng Wu ,  Chao-Yang Huang ,  Ya-Wei Tsai ,  Ying-Yung Lok ,  Chung-Hsiun Wu ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

    IPC分类号： A61K39/395 ,  C07K16/40 ,  A61K39/00

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

    摘要： A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

    摘要翻译： 人源化抗体或其结合片段，其中所述人源化抗体结合人ENO1（GenBank：AAH50642.1），其中所述抗体包含轻链可变区（VL）结构域，其包含具有氨基酸序列LCDR1（RASENIYSYLT; SEQ ID NO：6）和具有氨基酸序列LCDR2（NAKTLPE; SEQ ID NO：7）的CDR2和具有氨基酸序列LCDR3（QHHYGTPYT; SEQ ID NO：8）和抗体重链可变区（ VH）结构域，其包含具有氨基酸序列HCDR1（GYTFTSCVMN; SEQ ID NO：3）的CDR1，具有氨基酸序列HCDR2（YINPYNDGTKYNEKFKG; SEQ ID NO：4）的CDR2和具有氨基酸序列HCDR3（EGFYYGNFDN ; SEQ ID NO：5），其中轻链可变区（VL）结构域和重链可变区（VH）结构域中的构架区包含来自人免疫球蛋白的氨基酸序列。

    Anti-granulysin antibodies and methods of use thereof
    5.
    发明授权
    Anti-granulysin antibodies and methods of use thereof 有权
    抗颗粒溶素抗体及其使用方法

    公开(公告)号：US09428575B2

    公开(公告)日：2016-08-30

    申请号：US14145583

    申请日：2013-12-31

    申请人： Development Center for Biotechnology ,  DCB-USA LLC

    发明人： Jiann-Shiun Lai ,  Hung-Ling Wang ,  Chao-Yang Huang ,  Ying-Yung Lok ,  Yuan-Tsong Chen ,  Woan-Eng Chan ,  Chih-Yung Hu

    IPC分类号： C07K16/18

    CPC分类号： C07K16/18 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

    摘要： An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

    摘要翻译： 能够结合到颗粒溶素的R64至R113的表位区并能够中和颗粒溶素活性的抗颗粒溶素抗体或其scFv或Fab片段。 抗体可以含有选自SEQ ID NO：82至SEQ ID NO：195的序列的序列，或者抗体可以含有选自SEQ ID NO：39至SEQ ID NO：76的序列的序列。 抗体可以是单克隆抗体。 用于治疗或预防不需要的免疫应答障碍的方法包括向有需要的受试者施用有效量的能够中和颗粒溶素活性的抗颗粒溶素抗体。 不想要的免疫应答障碍可以是SJS，TEN或GVHD。

    HUMANIZED ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY
    6.
    发明申请
    HUMANIZED ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY 有权
    人类ALPHA-ENOLASE特异性抗体及其在癌症治疗中的使用方法

    公开(公告)号：US20160185876A1

    公开(公告)日：2016-06-30

    申请号：US14588212

    申请日：2014-12-31

    申请人： Development Center for Biotechnology ,  DCB-USA LLC ,  National Health Research Institutes

    发明人： Shih-Chong Tsai ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Jiann-Shiun Lai ,  Chia-Cheng Wu ,  Chao-Yang Huang ,  Ya-Wei Tsai ,  Ying-Yung Lok ,  Chung-Hsiun Wu ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

    IPC分类号： C07K16/40

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

    摘要： A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

    摘要翻译： 人源化抗体或其结合片段，其中所述人源化抗体结合人ENO1（GenBank：AAH50642.1），其中所述抗体包含轻链可变区（VL）结构域，其包含具有氨基酸序列LCDR1（RASENIYSYLT; SEQ ID NO：6）和具有氨基酸序列LCDR2（NAKTLPE; SEQ ID NO：7）的CDR2和具有氨基酸序列LCDR3（QHHYGTPYT; SEQ ID NO：8）和抗体重链可变区（ VH）结构域，其包含具有氨基酸序列HCDR1（GYTFTSCVMN; SEQ ID NO：3）的CDR1，具有氨基酸序列HCDR2（YINPYNDGTKYNEKFKG; SEQ ID NO：4）的CDR2和具有氨基酸序列HCDR3（EGFYYGNFDN ; SEQ ID NO：5），其中轻链可变区（VL）结构域和重链可变区（VH）结构域中的构架区包含来自人免疫球蛋白的氨基酸序列。

    HUMANIZED ANTIBODY AGAINST INTERLEUKIN-20 AND TREATMENT FOR INFLAMMATORY DISEASES
    7.
    发明申请
    HUMANIZED ANTIBODY AGAINST INTERLEUKIN-20 AND TREATMENT FOR INFLAMMATORY DISEASES 审中-公开
    人类抗逆转录酶-2抗体和治疗炎症性疾病

    公开(公告)号：US20160068595A1

    公开(公告)日：2016-03-10

    申请号：US14785139

    申请日：2014-04-18

    申请人： Development Center for Biotechnology ,  DCB-USA LLC

    发明人： Chia-Cheng Wu ,  Chao-Yang Huang ,  Yu-Ying Lin ,  Yu-Jung Chen ,  Jiann-Shiun Lai

    IPC分类号： C07K16/24

    CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

    摘要： A humanized antibody, or a scFv, Fab, or F(ab′)2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.

    摘要翻译： 人源化抗体或其scFv，Fab或F（ab'）2包括：重链可变区或其同源变体，其中重链可变区包括：重链框架区，CDRH1具有 SEQ ID NO：19的序列，具有SEQ ID NO：20的序列的CDRH2和具有SEQ ID NO：21的序列的CDRH3，其中所述重链可变区和所述同源变体具有至少90％的序列同一性 在重链框架地区; 和轻链可变区或其同源变体，其包括：轻链框架区，具有SEQ ID NO：22的序列的CDRL1，具有SEQ ID NO：23的序列的CDRL2和具有SEQ ID NO：23的CDRL3，其具有 SEQ ID NO：24的序列，其中轻链可变区和同源变体在轻链框架区中共享至少90％的序列同一性。

    ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE THEREOF
    8.
    发明申请
    ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE THEREOF 有权
    抗粒细胞抗原及其使用方法

    公开(公告)号：US20140186352A1

    公开(公告)日：2014-07-03

    申请号：US14145583

    申请日：2013-12-31

    申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY

    发明人： Jiann-Shiun Lai ,  Hung-Ling Wang ,  Chao-Yang Huang ,  Ying-Yung Lok

    IPC分类号： C07K16/18

    CPC分类号： C07K16/18 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

    摘要： An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

    摘要翻译： 能够结合到颗粒溶素的R64至R113的表位区并能够中和颗粒溶素活性的抗颗粒溶素抗体或其scFv或Fab片段。 抗体可以含有选自SEQ ID NO：82至SEQ ID NO：195的序列的序列，或者抗体可以含有选自SEQ ID NO：39至SEQ ID NO：76的序列的序列。 抗体可以是单克隆抗体。 用于治疗或预防不需要的免疫应答障碍的方法包括向有需要的受试者施用有效量的能够中和颗粒溶素活性的抗颗粒溶素抗体。 不想要的免疫应答障碍可以是SJS，TEN或GVHD。